Market Access

Pushing for access wins in quickly evolving market and digital health landscapes.

Challenging six misconceptions that have characterized product strategies in Central and Eastern European markets.

Webinar Date/Time: Mon, Jul 28, 2025 11:00 AM EDT

While the growing oncology pipeline offers tremendous potential, the path from clinical development through to commercial launch and patient administration is complex and lined with challenges that can impact product success and access.

Q&A with Model N's Michael Grosberg drills deeper into the new US drug pricing directives, including challenges in implementation, the potential unintended consequences, and how these actions could spark the shift to outcomes-based contracting in healthcare.

Not lost in the mix of June's wide-ranging coverage in Pharmaceutical Executive is an honest take on what guest thought leaders argue is “undoubtedly” the hardest job in biopharma.

Special Guest Opinion: A reimagined regulatory framework for the life sciences is not just pro-investor—it is pro-patient.

These diseases require specialty treatment typically unavailable at local retail pharmacies or small health systems, making it extremely difficult for many patients to get the care they need.

In today’s environment, aligning the Target Product Profile with the appropriate Value Evidence Archetype is not just good practice, it is a strategic imperative.

Heparin is a critical drug that is highly dependent on the global supply chain and is derived from a highly complex process.

Demand for semaglutide and other GLP-1s is expected to grow exponentially over the next 3–5 years.

As the FDA’s ban on mass compounding of semaglutide takes effect, Novo Nordisk introduces discounted pricing and new patient resources to ensure safe access to Wegovy.

The window of opportunity for launch is short and unforgiving, and the success depends on flawless execution of launch activity across countries and functions.

Identifying the priorities that translate to strong business outcomes—and separating the top performers from the average brands.

Navigating technology and regulatory shifts in pharma revenue management.

Country is poised to offer growth-channel opportunities for global pharma companies ready to scale access, innovation, and profitability.

The argument for weighing clinical points more heavily in the access equation.

A seminar shares key observations and learnings from the first round of direct price negotiations.

Market access is about aligning internal strategies with external realities that often change without warning and at a frequency likely not experienced by other biopharma executive roles.

CMS’ draft guidance on real-world data study protocols marks a significant move toward transparency and rigor in Medicare coverage decisions.

Four tips for midsized companies when entering new global markets.

How to maximize market-entry performance for new pharma products in an increasingly competitive launch environment.

“We’re going to tariff our pharmaceuticals, and once we do that, they are going to come rushing back into our country," President Donald J. Trump said during a Tuesday night dinner in Washington.

The high-stakes nature of cancer care, coupled with rapid scientific advancements and increasing payer and regulatory pressures, demands a specialized approach beyond traditional market access strategies.

A look at the current landscape and how young companies can set the stage for product launch.

HEOR scientists in the pharma industry must balance methodologic rigor with commercial expectations and timelines.

The recent shift in Health Economics and Outcomes Research functions across major pharmaceutical companies highlights a lack of understanding of its value.

Biopharmas and global agencies are now prioritizing initiatives and innovations to drive speed across product development with an emphasis on getting new treatments in the hands of doctors and patients.

Demonstrating clinical benefit is the ultimate gateway to smoother patient access.

As part of the Inflation Reduction Act, price negotiations with manufacturers will begin this year, with reduced prices expected to take effect in 2027.